Skip to Main Content

Investor Relations


HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

We plan to initiate a Phase 2b study in the second quarter of 2022 to evaluate the safety, immunogenicity, and efficacy of HIL-214 in infants. We expect to report interim safety data from this trial for the first 200 subjects in the second half of 2022, interim immunogenicity data for the first 200 subjects in the first half of 2023, and top-line data in the second half of 2023. In addition to infants, we also plan to seek approval of HIL-214 in additional age groups such as older children, adults, and older adults.

HilleVax has assembled a distinguished team with experience in vaccine development, clinical trial operations, manufacturing, and commercialization, including prior experiencing developing HIL-214 at Takeda Pharmaceuticals.

Stock Information

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.


10 Nov '22
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4 th Annual Immunology and Neurology Day and the Stifel

Recent Events

Featured Reports